- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03839628
Translational Control of Anabolic Resistance in Aging Muscle
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pre-testing- The baseline evaluation will assess muscle function and strength, and an oral glucose tolerance test. After the baseline visit, participants will be provided with a step activity monitor to track their level of activity. This will provide a baseline of the participant's normal level of physical activity so an accurate level of 75% activity reduction can be determined. A 3-day daily dietary diary will be provided for the participant to self-report prior to the experiment, as well.
Day 1- After the participant completes their normal activity log and dietary diary, they will be asked to return to the research center for a body composition scan and a metabolic study.
The metabolic study will involve blood sampling from an arm vein and muscle biopsies from the thigh before and after a leucine drink.
2-week period of inactivity- After the metabolic study, the participant will return home and maintain a reduced level of activity (75% reduction) for a two-week period. During this time, the participant will receive phone calls from research personnel in order to maintain adherence to the intervention.
Day 14- After the 2-week reduced activity period, the participant will return to the research center to receive a body composition scan and undergo a metabolic study identical to 'Day 1'.
Post-testing- After Day 14, the participant will be asked to return once again to the research center for a oral glucose tolerance test and the exercise lab for muscle function testing.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 60-85 years
- Ability to sign informed consent
- Free-living, prior to admission
Exclusion Criteria:
- Cardiac abnormalities considered exclusionary by the study physician (e.g., Chronic heart Failure, right-to-left shunt)
- Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes)
- History of kidney disease or failure
- Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia > 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries)
- Risk of blood clotting including family history of thrombophilia, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb>18 g/dL) or thrombocytosis (platelets>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III
- Use of anticoagulant therapy (e.g., Coumadin, heparin)
- Elevated systolic pressure >150 or a diastolic blood pressure > 100
- Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
- Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
- Currently on a weight-loss diet or body mass index > 30 kg/m2
- Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted). Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted)
- History of stroke with motor disability
- A recent history (<12 months) of GI bleed
- History of liver disease
- History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
- Prior history of Heparin-Induced Thrombocytopenia
- An HbA1c value at or greater than 6.5%
- Any other condition or event considered exclusionary by the PI and faculty physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reduced Physical Activity
Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
|
Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean Mass
Time Frame: baseline and 2-weeks
|
Change in lean mass
|
baseline and 2-weeks
|
Strength
Time Frame: baseline and 2-weeks
|
Change in muscle strength
|
baseline and 2-weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Leucine study
- R21AR073422 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Physical Inactivity
-
University of Alabama at BirminghamRecruitingDisability Physical | Physical InactivityUnited States
-
University of IowaNational Institute on Aging (NIA); Northeastern UniversityNot yet recruiting
-
Ludwig Boltzmann Institute for Digital Health and...RecruitingPhysical InactivityAustria
-
University of MichiganNational Institute on Aging (NIA)Recruiting
-
University of MinnesotaRecruitingPhysical InactivityUnited States
-
Brown UniversityNational Cancer Institute (NCI)Recruiting
-
Universiti Putra MalaysiaRecruitingInactivity, PhysicalPakistan
-
University of Milano BicoccaFederico II University; University of BergamoRecruitingPhysical InactivityItaly
-
Brown UniversityNational Institute of General Medical Sciences (NIGMS)Not yet recruitingPhysical InactivityUnited States
-
University of CalgaryPublic Health Agency of Canada (PHAC)Recruiting
Clinical Trials on Reduced Physical Activity
-
Virginia Commonwealth UniversityCompleted
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | ObesityUnited States
-
University of BirminghamMaastricht UniversityCompletedSedentary LifestyleUnited Kingdom
-
University of BathCompletedMuscular AtrophyUnited Kingdom
-
University of TorontoRecruitingSarcopenia | Aging | Sedentary Behavior | Amino Acids | Dietary ProteinCanada
-
Oregon Health and Science UniversityRecruitingSleep | Sedentary Behavior | Cardiovascular FunctionUnited States
-
University of TorontoRecruitingPhysical Inactivity | Resistance Exercise | Amino Acids | Dietary ProteinCanada
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan